Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 226-232

  Joly, Florence ^a   Ray Coquard, Isabelle ^b   Fabbro, Michel ^c   Donoghoe, Mark ^d   Boman, Karin ^e   Sugimoto, Akira ^f   Vaughan, Michelle ^g   Reinthaller, Alexander ^h   Vergote, Ignace ⁱ   Ferrandina, Gabriella ^j   Dell'Anna, Tiziana ^k   Huober, Jens ^l   Pujade Lauraine, Eric ^m  

^a CHU CÔTE DE NACRE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE VAL D AURELLE   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f London Regional Cancer Centre   (United Kingdom)

^g CHRISTCHURCH HOSPITAL   (New Zealand)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j CATHOLIC UNIVERSITY   (Italy)

^k SAN GERARDO HOSPITAL   (Italy)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Allergy; Carboplatin; Hypersensitivity reaction(s); Ovarian cancer; Pegylated liposomal doxorubicin

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

AGED; ALLERGY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 79960444334     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.019     Document Type: Article

References (46)

1. K. Aabo, M. Adams, P. Adnitt, D.S. Alberts, A. Athanazziou, V. Barley, D.R. Bell, U. Bianchi, G. Bolis, M.F. Brady, H.S. Brodovsky, H. Bruckner, M. Buyse, R. Canetta, V. Chylak, C.J. Cohen, N. Colombo, P.F. Conte, D. Crowther, J.H. Edmonson, C. Gennatas, E. Gilbey, M. Gore, D. Guthrie, and B.Y. Yeap Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials. Advanced Ovarian Cancer Trialists' Group Br J Cancer 78 1998 1479 1487 (Pubitemid 28517545)
2. Advanced Ovarian Cancer Trialists Group Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials Br Med J 303 1991 884 893
3. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, S.L. Lentz, R.D. Alvarez, P.R. Kucera, and J.M. Small Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 18 2000 106 115 (Pubitemid 30036343)
4. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211 (Pubitemid 20061287)
5. A.K. Sood, M.S. Gelder, S.W. Huang, and L.S. Morgan Anaphylaxis to carboplatin following multiple previous uncomplicated courses Gynecol Oncol 57 1995 131 132
6. P.G. Rose, N. Fusco, L. Fluellen, and M. Rodriguez Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma Int J Gynecol Cancer 8 1998 365 368 (Pubitemid 28541666)
7. M. Markman, A. Kennedy, K. Webster, P. Elson, G. Peterson, B. Kulp, and J. Belinson Clinical features of hypersensitivity reactions to carboplatin J Clin Oncol 17 1999 1141 1145 (Pubitemid 29162937)
8. A. Polyzos, N. Tsavaris, C. Kosmas, T. Arnaouti, N. Kalahanis, C. Tsigris, A. Giannopoulos, G. Karatzas, L. Giannikos, and P.P. Sfikakis Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience Oncology 61 2001 129 133 (Pubitemid 32786206)
9. M. Navo, A. Kunthur, M.L. Badell, L.W. Coffer, M. Markman, J. Brown, and J.A. Smith Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients Gynecol Oncol 103 2006 608 613 (Pubitemid 44602175)
10. S. Sliesoraitis, and P.J. Chikhale Carboplatin hypersensitivity Int J Gynecol Cancer 15 2005 13 18 (Pubitemid 40194327)
11. B. Weidmann, N. Mulleneisen, P. Bojko, and N. Niederle Hypersensitivity reactions to carboplatin: report of two patients, review of the literature, and discussion of diagnostic procedures and management Cancer 73 1994 2218 2222 (Pubitemid 24107980)
12. S.M. Chang, S. Fryberger, V. Crouse, D. Tilford, and M.D. Prados Carboplatin hypersensitivity in children Cancer 75 1995 1171 1175
13. H. Kook, K.M. Kim, S.H. Choi, B.S. Choi, H.J. Kim, S.Y. Chung, S.J. Choi, and T.J. Hwang Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization Bone Marrow Transplant 21 1998 727 729 (Pubitemid 28159612)
14. S.M. Zweizig, L.D. Roman, and L.I. Muderspach Death from anaphylaxis to cisplatin: a case report Gynecol Oncol 5 1994 121 122
15. M.J. Kandel, A. Loehr, P. Harter, A. Traut, K. Gnauert, and A. du Bois Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity Int J Gynecol Cancer 15 2005 780 784 (Pubitemid 41783081)
16. J.R. Schwartz, C. Bavdera, A. Bradley, L. Brard, R. Legare, C.O. Granai, and D.S. Dizon Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital Gynecol Oncol 105 2007 81 83 (Pubitemid 46441444)
17. A. Goldberg, R. Confino-Cohen, A. Fishman, Y. Beyth, and M. Altaras A modified, prolonged desensitization protocol in carboplatin allergy J Allergy Clin Immunol 98 1996 841 843 (Pubitemid 26357252)
18. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, P.A. Vasey, B. Volgger, I. Vergote, S. Pignata, A. Ferrero, J. Sehouli, A. Lortholary, G. Kristensen, C. Jackisch, F. Joly-Lobbedez, C. Brown, N. Le Fur, A. du Bois, and on behalf of the GCIG (Gynecologic Cancer InterGroup) of GINECO, AGO-OVAR, NSGO, ANZGOG, NCIC-CTG, AGO-Austria, EORTC, MITO, and MaNGO Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
19. http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcaev3.pdf
20. A. Gadducci, R. Tana, G. Teti, G. Zanca, A. Fanucchi, and A.R. Genazzani Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer Int J Gynecol Cancer 18 2008 615 620 (Pubitemid 352020152)
21. H. Koshiba, K. Hosokawa, A. Kubo, Y. Miyagi, T. Oda, Y. Miyagi, A. Watanabe, and H. Honjo Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies Int J Gynecol Cancer 19 2009 460 465
22. S. Pignata, S. De Placido, R. Biamonte, G. Scambia, G. Di Vagno, G. Colucci, A. Febbraro, M. Marinaccio, A.V. Lombardi, L. Manzione, G. Cartenì, M. Nardi, S. Danese, M. Valerio, A. De Matteis, B. Massidda, G. Gasparini, M. Di Maio, C. Pisano, and F. Perrone Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study BMC Cancer 6 2006 5 11
23. D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H.P. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides, and A.M. Dimopoulos A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study BMC Med 8 2010 3 14
24. M. Markman, J. Moon, S. Wilczynski, A.M. Lopez, K.M. Rowland Jr., D.P. Michelin, V.J. Lanzotti, G.L. Anderson, and D.S. Alberts Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial Gynecol Oncol 166 3 2010 323 325
25. J.M. Ferrero, B. Weber, J.F. Geay, D. Lepille, H. Orfeuvre, M. Combe, F. Mayer, B. Leduc, H. Bourgeois, D. Paraiso, and E. Pujade-Lauraine Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann Oncol 18 2 2007 263 268 (Pubitemid 46323091)
26. P. Power, G. Stuart, A. Oza, D. Provencher, Bentley Jr., W.H. Miller Jr., and J.F. Pouliot Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study Gynecol Oncol 114 3 2009 410 414
27. J.S. Morgan, M. Adams, and M.D. Mason Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma Eur J Cancer 30A 8 1994 1205 1206 (Pubitemid 24277855)
28. P.E. Hesterberg, A. Banerji, E. Oren, R.T. Penson, C.N. Krasner, M.V. Seiden, and J.T. Wong Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management J Allergy Clin Immunol 123 6 2009 1262 1267
29. K.M. Zanotti, L.A. Rybicki, A.W. Kennedy, J.L. Belinson, K.D. Webster, B. Kulp, G. Peterson, and M. Markman Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy J Clin Oncol 19 2001 3126 3129 (Pubitemid 32565451)
30. M. Markman, K. Zanotti, B. Kulp, G. Peterson, and M. Markman Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity Gynecol Oncol 89 2003 514 516 (Pubitemid 36687801)
31. M. Markman The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management Gynecol Oncol 107 2007 163 165 (Pubitemid 47592866)
32. A. Du Bois, J. Pfisterer, N. Burchardi, S. Loibl, J. Huober, P. Wimberger, A. Burges, A. Stahle, C. Jackisch, and H. Kolbl Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut) Gynecol Oncol 107 3 2007 518 525 (Pubitemid 350160867)
33. K.S. Tonkin, P. Rubin, and L. Levin Carboplatin hypersensitivity: case reports and review of the literature Eur J Cancer 29A 9 1993 1356 1357 (Pubitemid 23169916)
34. R.G. Hamilton, D.W. MacGlaashan Jr., and S.S. Saini IgE antibody-specific activity in human allergic disease Immunol Res 47 2010 273 284
35. M. Raulf-Heimsoth, R. Merget, H.P. Rihs, M. Föhring, V. Liebers, B. Gellert, G. Schultze-Werninghaus, and X. Baur T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt Eur Respir J 16 5 2000 871 878 (Pubitemid 32049373)
36. W.J. Pichler Delayed drug hypersensitivity reactions Ann Intern Med 139 8 2003 683 693
37. J.M. Harris, N.E. Martin, and M. Modi Pegylation: a novel process for modifying pharmacokinetics Clin Pharmacokinet 40 7 2001 539 551 (Pubitemid 32738660)
38. M. Hamidi, A. Azadi, and P. Rafiei Pharmacokinetic consequences of pegylation Drug Deliv 13 6 2006 399 409 (Pubitemid 44470219)
39. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J Pharm Sci 97 10 2008 4167 4183
40. H. Koide, T. Asai, K. Hatanaka, S. Akai, T. Ishii, E. Kenio, T. Ishida, H. Kiwada, H. Tsukada, and N. Oku Tcell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes Int J Pharm 392 2010 223
41. Y. Gernez, F. Barlesi, P. Astoul, and A. Magnan Hypersensibilité au carboplatine: un rôle pour les génériques? Rev Mal Respir 23 2006 269 272
42. R. O'Cearbhaill, Q. Zhou, A. Iasonos, Hensley Ml, W.P. Tew, C. Aghajanian, D.R. Spriggs, S.M. Lichtman, and P.J. Sabbatini The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment Gynecol Oncol 116 3 2010 326 331
43. K.M. Zanotti, and M. Markman Prevention and management of antineoplastic-induced hypersensitivity reactions Drug Saf 24 10 2001 767 779 (Pubitemid 32848355)
44. C. Lee, M. Gianos, and W.B. Klaustermeyer Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents Ann Allergy Asthma Immunol 102 2009 179 187
45. M.C. Castells, N.M. Tennant, D.E. Sloane, F.I. Hsu, N.A. Barrett, D.I. Hong, T.M. Laidlaw, H.J. Legere, S.N. Nallamshetty, R.I. Palis, J.J. Rao, S.T. Berlin, S.M. Campos, and U.A. Matulonis Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases J Allergy Clin Immunol 122 2008 574 580
46. M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity J Clin Oncol 21 2003 4611 4614 (Pubitemid 46594035)